<DOC>
	<DOCNO>NCT02901483</DOCNO>
	<brief_summary>It 's prospective , open-label , single arm , nonrandomized study PEP503 head neck squamous cell carcinoma ( HNSCC ) patient . - Escalation portion ( Phase 1b ) : A 3 + 3 dose escalation study design adopt phase identify recommend intratumor injection volume PEP503 . - Expansion portion ( Phase 2 ) : Following confirmation recommend volume , 18 additional patient enrol recommended volume level evaluate safety efficacy .</brief_summary>
	<brief_title>A Study PEP503 With Radiotherapy Combination With Concurrent Chemotherapy Patients With Head Neck Cancer</brief_title>
	<detailed_description>Primary Objectives : - Phase 1b ( dose escalation portion ) : To assess safety profile determine Dose Limiting Toxicity ( DLT ) define recommend volume ( dos ) PEP503 . - Phase 2 ( expansion portion ) : To evaluate anti-tumor activity term rate locoregional control one year evaluate safety profile . Secondary Objectives : - Phase 1b : To characterize body kinetic profile PEP503 . - Phase 2 : Objective tumor response , progression free survival rate 1 year pathological response ( pR ) . The target population compose patient pathologically confirm squamous cell carcinoma oral cavity disease clinically stag T4b candidate surgical resection T3-4 decline surgery medical inoperable , without metastasis disease . ECOG performance status 0 1 adequate bone marrow , renal , hepatic function . Dose limit toxicity ( DLT ) - The DLTs related PEP503 , injection procedure , concurrent chemo radiation therapy occur DLT evaluation period . The DLT evaluation period start intratumor injection PEP503 4 week completion radiation treatment . There 4 level ( Level 1 , Level 2 , Level 3 Level 4 correspond 5 % , 10 % , 15 % 22 % total baseline tumor volume , respectively ) phase 1b study . PEP503 give fix concentration 53.3g/L . The starting volume PEP503 inject 5 % ( Level 1 ) tumor volume confirm MRI .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm squamous cell carcinoma ( SCC ) oral cavity Advanced recurrent disease : T4b , N , candidate surgical resection ; T34 , N , decline surgery medical inoperable No evidence distant metastatic disease , determine negative PET scan CT scan ECOG Performance Status 0 1 Adequate function bone marrow , kidney liver : White Blood Cell ( WBC ) ≥ 3.0 x 109/l Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l Platelet count ≥ 100 x 109/l Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 x ULN AST ≤ 2.5 x ULN , ALT ≤ 2.5 x ULN Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN Bilirubin ≤ 1.5 x ULN 20 year age old All female patient childbearing potential must negative urine pregnancy test within 7 day prior study treatment PEP503 . Fertile patient must agree use effective contraception study Tumor ulceration combine vascular risk Prior radiotherapy area within plan radiotherapy field Uncontrolled intercurrent illness Concurrent treatment anticancer therapy Participation investigational drug study within 4 week Prior concurrent nonhead neck malignancy , exclude adequately treat basal squamous cell cancer skin , situ cervical cancer , cancer subject cancer free 5 year Patients unable comply schedule visit study procedure . Preexisting neuropathy ≥ 2 History allergic reaction platinum product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Head Neck</keyword>
</DOC>